Literature DB >> 28882220

Cancer Hallmarks and MicroRNAs: The Therapeutic Connection.

Katrien Van Roosbroeck1, George A Calin2.   

Abstract

Human cancers are characterized by a number of hallmarks, including sustained proliferative signaling, evasion of growth suppressors, activated invasion and metastasis, replicative immortality, angiogenesis, resistance to cell death, and evasion of immune destruction. As microRNAs (miRNAs) are deregulated in virtually all human cancers, they show involvement in each of the cancer hallmarks as well. In this chapter, we describe the involvement of miRNAs in cancer from a cancer hallmarks and targeted therapeutics point of view. As no miRNA-based cancer therapeutics are available to date, and the only clinical trial on miRNA-based cancer therapeutics (MRX34) was terminated prematurely due to serious adverse events, we are focusing on protein-coding miRNA targets for which targeted therapeutics in oncology are already approved by the FDA. For each of the cancer hallmarks, we selected major protein-coding players and describe the miRNAs that target them.
© 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer hallmarks; Coding gene targets; Immunotherapy; Invasion; MicroRNAs; Proliferation; Targeted therapy

Mesh:

Substances:

Year:  2017        PMID: 28882220     DOI: 10.1016/bs.acr.2017.06.002

Source DB:  PubMed          Journal:  Adv Cancer Res        ISSN: 0065-230X            Impact factor:   6.242


  53 in total

Review 1.  Role of miRNAs in immune responses and immunotherapy in cancer.

Authors:  Maria Angelica Cortez; Simone Anfossi; Rishab Ramapriyan; Hari Menon; Semra Cemre Atalar; Maureen Aliru; James Welsh; George A Calin
Journal:  Genes Chromosomes Cancer       Date:  2019-04       Impact factor: 5.006

Review 2.  Emerging roles of non-coding RNAs in the pathogenesis, diagnosis and prognosis of osteosarcoma.

Authors:  Chongchong Wang; Juehua Jing; Li Cheng
Journal:  Invest New Drugs       Date:  2018-08-06       Impact factor: 3.850

3.  Identification of common microRNA between COPD and non-small cell lung cancer through pathway enrichment analysis.

Authors:  Amirhossein Fathinavid; Mohadeseh Zarei Ghobadi; Ali Najafi; Ali Masoudi-Nejad
Journal:  BMC Genom Data       Date:  2021-10-12

4.  MicroRNA-222 alleviates radiation-induced apoptosis by targeting BCL2L11 in cochlea hair cells.

Authors:  Yan-Yan Zhang; Gao-Yun Xiong; Xiao-Xing Xie
Journal:  Biosci Rep       Date:  2021-06-25       Impact factor: 3.840

5.  Silencing miRNA-1297 suppresses the invasion and migration of prostate cancer cells via targeting modulation of PTEN and blocking of the AKT/ERK pathway.

Authors:  Lei Wang; Jing Gao; Yu Zhang; Shaosan Kang
Journal:  Exp Ther Med       Date:  2021-05-17       Impact factor: 2.447

6.  CircFAM53B promotes the proliferation and metastasis of glioma through activating the c-MET/PI3K/AKT pathway via sponging miR-532-3p.

Authors:  Jiaping Pei; Hui Dou; Xiaozhao Deng
Journal:  Cell Cycle       Date:  2022-01-31       Impact factor: 4.534

Review 7.  Dysregulation of microRNAs in metal-induced angiogenesis and carcinogenesis.

Authors:  Lin Wang; Ling-Zhi Liu; Bing-Hua Jiang
Journal:  Semin Cancer Biol       Date:  2021-08-21       Impact factor: 15.707

Review 8.  MicroRNAs: understanding their role in gene expression and cancer.

Authors:  Ariany Lima Jorge; Erik Ribeiro Pereira; Christian Sousa de Oliveira; Eduardo Dos Santos Ferreira; Edmara Toledo Ninzoli Menon; Susana Nogueira Diniz; Julia Alejandra Pezuk
Journal:  Einstein (Sao Paulo)       Date:  2021-07-16

9.  Circulating miRNAs in Serum as Biomarkers for Early Diagnosis of Non-small Cell Lung Cancer.

Authors:  Xiaotong Duan; Simiao Qiao; Dianhe Li; Shangbiao Li; Zhihao Zheng; Qin Wang; Xiaoxia Zhu
Journal:  Front Genet       Date:  2021-07-09       Impact factor: 4.599

10.  MicroRNA-155-5p promotes cell proliferation and invasion in lung squamous cell carcinoma through negative regulation of fibroblast growth factor 9 expression.

Authors:  Feng Liu; Qing Mao; Shaojin Zhu; Junlan Qiu
Journal:  J Thorac Dis       Date:  2021-06       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.